Flavio Crameri

TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.

TL;DR: FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.

TL;DR: Experimental evidence strongly suggests that activation of APAP and subsequent formation of protein adducts are involved in hepatotoxicity, and many of the proteins showing changed expression levels are either known targets for covalent modification by N‐acetyl‐p‐benzoquinoneimine (NAPQI) or involved in the regulation of mechanisms that are believed to drive APAP‐induced hepatot toxicity.

TL;DR: Analysis of mitochondrial proteins on 2D gels showed the upregulation of two proteins involved in stress (catalase and uricase) and the downregulated proteins, including some P450, were downregulated in the treated animals.

TL;DR: This article summarizes the presentations and discussions from both the main and the breakout sessions of the 5th European BioSafe Annual General Membership meeting in November 2015 in Ludwigshafen.